Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
DMIIR0.140USD
0.000
交易中 （美東）報價延遲15分鐘
--總市值
--本益比TTM
關於 Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 公司
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030簡介
公司代碼DMIIR
公司名稱Drugs Made In America Acquisition II Corp
上市日期Sep 25, 2025
CEOStockwell (Lynn)
員工數量- -
證券類型Right
年結日- -
公司地址1 East Broward Boulevard
城市FT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33301
電話19548703099
網址
公司代碼DMIIR
上市日期Sep 25, 2025
CEOStockwell (Lynn)
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
持股股東
股東類型
持股股東
持股股東
佔比
其他
100.00%
持股股東
持股股東
佔比
其他
100.00%
股東類型
持股股東
佔比
其他
100.00%
機構持股
由於公司未披露，未能獲取相關數據
報告期間
機構數
持股數
持股佔比
持股變動
暫無數據
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
暫無數據
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的前五大股東是誰？
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的前五大股東如下：
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的前三大股東類型是什麼？
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 的前三大股東類型分別是：
其他
其他
有多少機構持有Drugs Made In America Acquisition II Rights Exp 16 Sep 2030(DMIIR)的股份？
截至--，共有--家機構持有Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的股份，合計持有的股份價值約為--，占公司總股份的--% 。與--相比，機構持股有所增加，增幅為--。
哪個業務部門對Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的收入貢獻最大？
在--，--業務部門對Drugs Made In America Acquisition II Rights Exp 16 Sep 2030的收入貢獻最大，創收--，占總收入的--% 。
